9543 results
Cited 1 times since 2024 (0.9 per year)
source: EuropePMC
Cells,
Volume 13, Issue 19, 30 5 2024, Pages 1636
Pulmonary and Systemic Immune Profiles Following Lung Volume Reduction Surgery and Allogeneic Mesenchymal Stromal Cell Treatment in Emphysema.
Jia L, Li N, van Unen V, Zwaginga JJ, Braun J, Hiemstra PS, Koning F, Khedoe PPSJ, Stolk J
Emphysema in patients with chronic obstructive pulmonary disease (COPD) is characterized by progressive inflammation. Preclinical studies suggest that lung volume reduction surgery (LVRS) and mesenchymal stromal cell (MSC) treatment dampen inflammation. We investigated the effects of bone marrow-derived MSC (BM-MSC) and LVRS on circulating and pulmonary immune cell profiles in emphysema patients using mass cytometry. Blood and resected lung tissue were collected at the first LVRS (L1). Following...
Abstract
Medical science educator,
Volume 35, Issue 1, 25 4 2024, Pages 43-46
The Development and Implementation of a Parallel, Multi-Campus Medical Anatomy Curriculum Delivered with and without Cadavers.
Harvey W, Van Schaik L, Frizzell H, Wright J, Rank MM
A parallel, multi-campus anatomy curriculum was developed that could be delivered with or without body donor cadaveric teaching resources. This blended program includes asynchronous lectures, e-Learning modules, formative self-assessment, independent study, and synchronous hands-on practical sessions. Practical sessions at the metropolitan campus utilise professionally prepared body donor cadaveric teaching resources, whereas rural campus practical sessions use a combination of non-cadaveric res...
Abstract
Cited 3 times since 2024 (2.6 per year)
source: EuropePMC
The EMBO journal,
Volume 43, Issue 21, 25 4 2024, Pages 5260-5287
Chromatin protein complexes involved in gene repression in lamina-associated domains.
Manzo SG, Mazouzi A, Leemans C, van Schaik T, Neyazi N, van Ruiten MS, Rowland BD, Brummelkamp TR, van Steensel B
Lamina-associated domains (LADs) are large chromatin regions that are associated with the nuclear lamina (NL) and form a repressive environment for transcription. The molecular players that mediate gene repression in LADs are currently unknown. Here, we performed FACS-based whole-genome genetic screens in human cells using LAD-integrated fluorescent reporters to identify such regulators. Surprisingly, the screen identified very few NL proteins, but revealed roles for dozens of known chromatin re...
Abstract
Cited 3 times since 2024 (2.6 per year)
source: EuropePMC
Therapeutic drug monitoring,
Volume 47, Issue 1, 25 4 2024, Pages 4-31
Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Masuda S, Lemaitre F, Barten MJ, Bergan S, Shipkova M, van Gelder T, Vinks S, Wieland E, Bornemann-Kolatzki K, Brunet M, de Winter B, Dieterlen MT, Elens L, Ito T, Johnson-Davis K, Kunicki PK, Lawson R, Lloberas N, Marquet P, Millan O, Mizuno T, Moes DJAR, Noceti O, Oellerich M, Pattanaik S, Pawinski T, Seger C, van Schaik R, Venkataramanan R, Walson P, Woillard JB, Langman LJ
Abstract: The Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology established the second consensus report to guide therapeutic drug monitoring (TDM) of everolimus (EVR) and its optimal use in clinical practice 7 years after the first version was published in 2016. This version provides information focused on new developments that have arisen in the last 7 years. For the general aspects of the pharmacology and TDM of...
Abstract
Cited 4 times since 2024 (3.5 per year)
source: EuropePMC
JACC. Clinical electrophysiology,
Volume 10, Issue 12, 25 4 2024, Pages 2613-2624
Ventricular Tachycardia Substrates in Children and Young Adults With Repaired Tetralogy of Fallot.
Wallet J, Kimura Y, Blom NA, Jongbloed MRM, Bertels RA, Hazekamp MG, Zeppenfeld K
Background: Patients with repaired tetralogy of Fallot (rTOF) have a time-dependent increased risk of ventricular tachycardia (VT). Slow conducting anatomical isthmuses (SCAIs) are the dominant VT substrates in adults with rTOF. It is unknown if they are present at younger age. Objectives: This study aimed to characterize VT substrates in patients with rTOF
Abstract
Cited 9 times since 2024 (7.7 per year)
source: EuropePMC
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,
Volume 69, Issue 2, 24 4 2024, Pages 272-281
Editor's Choice - Role of Antiplatelet Therapy in Patients Managed for Complex Aortic Aneurysms using Fenestrated or Branched Endovascular Repair.
Nana P, Spanos K, Tsilimparis N, Haulon S, Sobocinski J, Gallitto E, Dias N, Eilenberg W, Wanhainen A, Mani K, Böckler D, Bertoglio L, van Rijswijk C, Modarai B, Seternes A, Enzmann FK, Giannoukas A, Gargiulo M, Kölbel T, APT-F/BEVAR Study Contributors
Objective: Despite the increasing number of fenestrated and branched endovascular aortic repair (F/B-EVAR) procedures, evidence on post-operative antiplatelet therapy is very limited. This study aimed to investigate the role of single antiplatelet therapy (SAPT) vs. double antiplatelet therapy (DAPT) after F/B-EVAR in 30 day and follow up outcomes. Methods: A multicentre retrospective analysis was conducted, including F/B-EVAR patients managed from 1 January 2018 to 31 December 2022. Comparative...
Abstract
Cited 1 times since 2024 (0.9 per year)
source: EuropePMC
European journal of heart failure,
Volume 27, Issue 7, 24 4 2024, Pages 1359-1361
Sexual dimorphism in the relationships between intramyocardial fat, myocardial fibrosis, and exercise intolerance in heart failure with preserved ejection fraction.
Ng ACT, Dong X, Koepp KE, Obokata M, Sorimachi H, Galloway G, Araoz P, Delgado V, Bax JJ, Borlaug BA
Abstract
Cited 6 times since 2024 (5.2 per year)
source: EuropePMC
Biosensors & bioelectronics,
Volume 267, 24 4 2024, Pages 116791
Dual action electrochemical bandage operated by a programmable multimodal wearable potentiostat.
Bozyel I, Fleming D, Won-Jun K, Rosen PF, Gelston S, Ozdemir D, Kies P, Koscianski C, Karau M, Ay SU, Patel R, Beyenal H
We have developed electrochemical bandage (e-bandage) prototypes that generate the reactive oxygen species hypochlorous acid (HOCl) or hydrogen peroxide (H2O2) for potential use to treat biofilm-infected wounds in humans. We have shown that both e-bandage-generated HOCl and H2O2 kill biofilms in vitro and in infected wounds on mice, with the former being more active in vitro. The H2O2-generating e-bandage, more so than the HOCl-generating e-bandage, was associated with improved healing of infect...
Abstract
Cited 3 times since 2024 (2.6 per year)
source: EuropePMC
JCI insight,
Volume 9, Issue 18, 24 4 2024, Pages e183674
Clinical cell-surface targets in metastatic and primary solid cancers.
Sharifi MN, Shi Y, Chrostek MR, Callahan SC, Shang T, Berg TJ, Helzer KT, Bootsma ML, Sjöström M, Josefsson A, Feng FY, Huffman LB, Schulte C, Blitzer GC, Sodji QH, Morris ZS, Ma VT, Meimetis L, Kosoff D, Taylor AK, LeBeau AM, Lang JM, Zhao SG
Therapies against cell-surface targets (CSTs) represent an emerging treatment class in solid malignancies. However, high-throughput investigations of CST expression across cancer types have been reliant on data sets of mostly primary tumors, despite therapeutic use most commonly in metastatic disease. We identified a total of 818 clinical trials of CST therapies with 78 CSTs. We assembled a data set spanning RNA-seq and microarrays in 7,927 benign samples, 16,866 primary tumor samples, and 6,124...
Abstract
Cited 1 times since 2024 (0.9 per year)
source: EuropePMC
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,
Volume 104, Issue 5, 23 4 2024, Pages 881-890
Procedural and clinical impact of intracoronary lithotripsy in heavily calcified aorto-ostial coronary lesions.
Oliveri F, Meijer M, Van Oort MJH, Al Amri I, Bingen BO, Claessen BE, Dimitriu-Leen AC, Kefer J, Girgis H, Vossenberg T, Van der Kley F, Jukema JW, Montero-Cabezas JM
Background: Percutaneous coronary intervention of calcified aorto-ostial lesions (AOL) pose unique challenges due to anatomical propensity for recoil, leading to poorer outcomes compared to non-AOL. Although intravascular lithotripsy (IVL) has shown excellent success and safety in heavily calcified plaques, evidence specific to AOL is limited. This study aims to evaluate the efficacy and safety of IVL in AOL versus non-AOL. Methods: Patients treated with IVL between 2019 and 2023 from an ongoing...
Abstract
Cited 29 times since 2024 (24.9 per year)
source: EuropePMC
Circulation,
Volume 150, Issue 24, 23 4 2024, Pages 1931-1943
Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial.
Stone GW, Lindenfeld J, Rodés-Cabau J, Anker SD, Zile MR, Kar S, Holcomb R, Pfeiffer MP, Bayes-Genis A, Bax JJ, Bank AJ, Costanzo MR, Verheye S, Roguin A, Filippatos G, Núñez J, Lee EC, Laufer-Perl M, Moravsky G, Litwin SE, Prihadi E, Gada H, Chung ES, Price MJ, Thohan V, Schewel D, Kumar S, Kische S, Shah KS, Donovan DJ, Zhang Y, Eigler NL, Abraham WT, RELIEVE-HF Investigators
Background: An interatrial shunt may provide an autoregulatory mechanism to decrease left atrial pressure and improve heart failure (HF) symptoms and prognosis. Methods: Patients with symptomatic HF with any left ventricular ejection fraction (LVEF) were randomized 1:1 to transcatheter shunt implantation versus a placebo procedure, stratified by reduced (≤40%) versus preserved (>40%) LVEF. The primary safety outcome was a composite of device-related or procedure-related major adverse cardiova...
Abstract
European heart journal open,
Volume 4, Issue 5, 23 4 2024, Pages oeae080
Short-term impact of cardiovascular screening by traditional risk assessment or coronary artery calcium score on health-related quality of life: the ROBINSCA trial.
Moldovanu D, de Koning HJ, Vonder M, Gratama JWC, Adriaansen HJ, Roeters van Lennep JE, Vliegenthart R, van der Harst P, Braam RL, van Dijkman PRM, Oudkerk M, van der Aalst CM
Aims: Evidence on the impact of screening for cardiovascular diseases (CVDs) on health-related quality of life (HRQoL) is important for policy decisions about screening implementation and to uncover teachable moments to motivate healthy lifestyle choices. It is unknown whether screening by cardiac computed tomography (CT) scan has a stronger impact on HRQoL than screening by traditional risk prediction models. The study aims to investigate differences in HRQoL across the screening process betwee...
Abstract
Cited 2 times since 2024 (1.7 per year)
source: EuropePMC
Frontiers in aging,
Volume 5, 20 3 2024, Pages 1365716
Unveiling frailty: comprehensive and sex-specific characterization in prematurely aging PolgA mice.
Yılmaz D, Singh A, Wehrle E, Kuhn GA, Mathavan N, Müller R
Frailty, a geriatric syndrome, is assessed using the frailty phenotype (FP) and frailty index (FI). While these approaches have been applied to aging mice, their effectiveness in prematurely aging mouse models such as PolgAD257A/D257A (PolgA) has not been completely explored. We demonstrated that frailty became evident in PolgA mice around 40 weeks, validated through body weight loss, reduced walking speed, decreased physical activity, and weaker grip strength. Moreover, we also identified sex d...
Abstract
Immunopharmacology and immunotoxicology,
Volume 46, Issue 6, 18 3 2024, Pages 805-814
Galantamine and wedelolactone combined treatment suppresses LPS-induced NLRP3 inflammasome activation in microglial cells.
Saker D, Sencar L, Coskun G, Sapmaz Ercakalli T, Yilmaz DM, Polat S
Context: Inflammasome NLR family pyrin domain-containing 3 (NLRP3) is associated with neurological disorders. Neuroinflammation can be suppressed by inhibiting NLRP3 inflammasome activation, decreasing neurodegenerative disorder progression. We devised a therapeutic technique that can reduce neuroinflammation induced by microglial activation, avoiding neurodegeneration. We aimed to investigate the mechanisms underlying the pharmacological effects of galantamine and wedelolactone by evaluating th...
Abstract
Cited 4 times since 2024 (3.4 per year)
source: EuropePMC
Heart & lung : the journal of critical care,
Volume 69, 17 3 2024, Pages 31-39
Modifiable risk factors and motivation for lifestyle change of CVD patients starting cardiac rehabilitation: The BENEFIT study.
Breeman LD, Pérez-Alonso A, Kühling-Romero D, Kraaijenhagen RA, Al-Dhahir I, IJzerman RVH, van Eersel R, Wolstencroft K, Bonten TN, Atsma DE, Chavannes NH, van Gemert-Pijnen L, Kemps HMC, Scholte Op Reimer W, Evers AWM, Janssen VR, BENEFIT consortium
Background: To improve lifestyle guidance within cardiac rehabilitation (CR), a comprehensive understanding of the motivation and lifestyle-supporting needs of patients with cardiovascular disease (CVD) is required. Objectives: This study's purpose is to evaluate patients' lifestyle and their motivation, self-efficacy and social support for change when starting CR. Methods: 1782 CVD patients (69 % male, mean age 62 years) from 7 Dutch outpatient CR centers participated between 2020 and...
Abstract
Cited 1 times since 2024 (0.8 per year)
source: EuropePMC
Research and practice in thrombosis and haemostasis,
Volume 8, Issue 7, 16 3 2024, Pages 102573
The impact of pulmonary embolism on health outcomes of COVID-19 at 3 months after hospitalization.
Visser C, Berentschot JC, de Jong CMM, Antoni ML, Bek LM, van den Berg-Emons RJG, van den Borst B, Ten Cate H, Ten Cate-Hoek AJ, Braeken DCW, Geelhoed JJM, Heijenbrok-Kal MH, van Kuijk SMJ, Kroft LJM, Leentjens J, Roukens AHE, Cannegieter SC, Klok FA, Kruip MJHA, Hellemons ME, Dutch COVID & Thrombosis Coalition@CovidDutch
Background: COVID-19 patients frequently experience pulmonary embolism (PE), but its long-term consequences remain uncertain. Objectives: To assess the impact of PE in COVID-19 patients on health outcomes at 3 months after hospitalization. Methods: In this multicenter cross-sectional study, we aggregated data from existing databases to evaluate the impact of PE on health outcomes at 3 months after hospitalization. We assessed 1) questionnaires on health-related quality of life (5-level EuroQol 5...
Abstract
Cited 27 times since 2024 (22.8 per year)
source: EuropePMC
Nature medicine,
Volume 30, Issue 11, 16 3 2024, Pages 3223-3235
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.
Nederlof I, Isaeva OI, de Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL, Garner H, Boeckx B, Traets JJH, Mandjes IAM, de Maaker M, van Brussel T, Chelushkin M, Champanhet E, Lopez-Yurda M, van de Vijver K, van den Berg JG, Hofland I, Klioueva N, Mann RM, Loo CE, van Duijnhoven FH, Skinner V, Luykx S, Kerver E, Kalashnikova E, van Dongen MGJ, Sonke GS, Linn SC, Blank CU, de Visser KE, Salgado R, Wessels LFA, Drukker CA, Schumacher TN, Horlings HM, Lambrechts D, Kok M
Immune checkpoint inhibition (ICI) with chemotherapy is now the standard of care for stage II-III triple-negative breast cancer; however, it is largely unknown for which patients ICI without chemotherapy could be an option and what the benefit of combination ICI could be. The adaptive BELLINI trial explored whether short combination ICI induces immune activation (primary end point, twofold increase in CD8+ T cells or IFNG), providing a rationale for neoadjuvant ICI without chemotherapy. Here, in...
Abstract
Cited 3 times since 2024 (2.5 per year)
source: EuropePMC
Nature communications,
Volume 15, Issue 1, 16 3 2024, Pages 8117
ENCORE: a practical implementation to improve reproducibility and transparency of computational research.
van Kampen AHC, Mahamune U, Jongejan A, van Schaik BDC, Balashova D, Lashgari D, Pras-Raves M, Wever EJM, Dane AD, García-Valiente R, Moerland PD
Reproducibility of computational research is often challenging despite established guidelines and best practices. Translating these guidelines into practical applications remains difficult. Here, we present ENCORE, an approach to enhance transparency and reproducibility by guiding researchers in how to structure and document a computational project. ENCORE builds on previous efforts in computational reproducibility and integrates all project components into a standardized file system structure....
Abstract
Cited 12 times since 2024 (10.1 per year)
source: EuropePMC
Clinical chemistry and laboratory medicine,
Volume 62, Issue 12, 13 2 2024, Pages 2373-2387
A vision to the future: value-based laboratory medicine.
Plebani M, Cadamuro J, Vermeersch P, Jovičić S, Ozben T, Trenti T, McMillan B, Lowe CR, Lennerz J, Macintyre E, Gabelli C, Sandberg S, Padoan A, Wiencek JR, Banfi G, Lubin IM, Orth M, Carobene A, Zima T, Cobbaert CM, van Schaik RHN, Lippi G
The ultimate goal of value-based laboratory medicine is maximizing the effectiveness of laboratory tests in improving patient outcomes, optimizing resources and minimizing unnecessary costs. This approach abandons the oversimplified notion of test volume and cost, in favor of emphasizing the clinical utility and quality of diagnostic tests in the clinical decision-making. Several key elements characterize value-based laboratory medicine, which can be summarized in some basic concepts, such as or...
Abstract
Cited 10 times since 2024 (8.4 per year)
source: EuropePMC
Communications biology,
Volume 7, Issue 1, 13 2 2024, Pages 1135
Nucleolus and centromere Tyramide Signal Amplification-Seq reveals variable localization of heterochromatin in different cell types.
Kumar P, Gholamalamdari O, Zhang Y, Zhang L, Vertii A, van Schaik T, Peric-Hupkes D, Sasaki T, Gilbert DM, van Steensel B, Ma J, Kaufman PD, Belmont AS
Genome differential positioning within interphase nuclei remains poorly explored. We extended and validated Tyramide Signal Amplification (TSA)-seq to map genomic regions near nucleoli and pericentric heterochromatin in four human cell lines. Our study confirmed that smaller chromosomes localize closer to nucleoli but further deconvolved this by revealing a preference for chromosome arms below 36-46 Mbp in length. We identified two lamina associated domain subsets through their differential nucl...
Abstract
